The Glycemic Explorer Challenge – Test Your Knowledge
Challenge yourself alongside Dr. Helen Baron to see if you know all of the treatment options for type 2 diabetes and their impact on patients’ HbA1c targets.
Welcome to the Glycemic Explorer Challenge series! I’m Dr. Helen Baron your host—and a clinical and academic endocrinologist. I’ll be challenging you on your knowledge of the complexities in type 2 diabetes and treatment, and sharing with you how your answers compare with thousands of your peers who have taken the challenge at various national meetings and conferences.
When it comes to treatment options for type 2 diabetes, there are many different types of medications, including both oral and injectable therapies.
Since 2000, do you know how many medications have become available for diabetes? Six, eleven, twenty-three or twenty-nine?
I’ll give you a few seconds to think about your answer, and then we’ll see how your peers responded.
Here we go.
So, when we challenged your peers with this question, just over half of them chose 29 medications, while the rest guessed quite low. And the ones who chose 29 are correct!
According to the FDA, during the last 16 years, approximately 29 different medications have become available for the treatment of diabetes. And actually this number is a little out of date given some of the recent activity in the market. In fact, there have been 37 different medications approved by the FDA for the treatment of type 2 diabetes since 2000.
So, with that in mind, let’s take a look at how many patients are reaching the ADA/AACE recommended target of 7% for most non-pregnant, healthy adults.
Here we have data from 1999 to 2010 that show the percentage of patients who had an A1c greater than or equal to 7%, despite the wide variety of treatment options. And while there has been progress, as you can see the most recent data shows that 47.8% of non-pregnant adults with diagnosed diabetes still had an A1c greater than 7%.
Let’s remember that ADA and AACE guidelines also point to lifestyle modifications, including diet, education, and exercise, as a foundation of T2DM management.
And here’s the study design for that data.
In summary, we can see that despite expanding treatment options, education, and resources, many patients are not reaching an A1C target of less than 7%. Therefore, it may be time to explore different treatment approaches that target the multiple physiologic complexities involved in type 2 diabetes.
So, when considering approaches for your patients who are uncontrolled, ask yourself, will your next move do enough?
Thanks for joining us. Look for more chances to challenge yourself with the other videos in this series.
Discover more here at GlycemicExplorer.com.